DOI: 10.6084/m9.figshare.10052219
title: Data supporting the figures and supplementary figures and tables in the published article: Suppression of FOXM1 activities and breast cancer growth in vitro and in vivo by a new class of compounds

description: In this study, the authors identified a new class of compounds effective in suppressing FOXM1 activity in breast cancers, and displaying good potency for antitumor efficacy.<br><b>Data access:</b> Datasets supporting figures 1-6, supplementary table 1 and supplementary figures 1, 2, 4 and 5 are publicly available in the figshare repository as part of this data record (<b>https://doi.org/10.6084/m9.figshare.10052219</b>). RNA-Seq data of the effects of compounds and of siFOXM1 on global <i>FOXM1</i> gene regulation, are publicly available in the NCBI Gene Expression Omnibus (GEO) repository at <b>https://identifiers.org/geo:GSE132343</b>.Uncropped Western blots are available as part of the supplementary information (supplementary figure 8).<br><b>Study approval:</b> All experiments involving animals were conducted in accordance with National Institutes of Health (NIH) standards for the care and use of animals, with protocols approved by the University of Illinois IACUC.<br><b>Study aims and methodology:</b>The transcription factor FOXM1 is up-regulated and overexpressed in aggressive, therapy resistant forms of hormone receptor-positive and triple negative breast cancers, and is associated with less good patient survival. FOXM1 signalling is also a key driver in many other cancers. This study aimed to investigate the suppressive activity of a new class of compounds on FOXM1 activity in breast cancers, and hence determine, whether these may be suitable for further clinical evaluation in targeting aggressive breast cancers driven by FOXM1. <br>The authors used a panel of human breast cancer cell lines and the non-tumorigenic MCF10A breast cell line that differed in their FOXM1 protein content (high to intermediate levels, DT22, MCF7, T47D, BT474, MDA-MB-453, MDA-MB-468, and MDA-MB-231 cells; and low level, MCF10A cells) to examine the effects of potential FOXM1 inhibitor compounds on cell proliferation.The chemical synthesis of compounds and their spectroscopic characterisation is described in detail in the Supplementary Information.The following procedures were carried out during the study and are described in detail in the published article: Cell viability (WST-1) assay, Western blot and immunofluorescence assays, Fluorescence binding assays with FOXM1, Drug affinity responsive target stability (DARTS) assay (to examine the effect of compounds on the stability of FOXM1 to proteolysis by exogenous pronase), Cell cycle analysis, Apoptosis analysis, Cytoplasmic and Nuclear extract preparation, RNA isolation and real-time PCR, RNA-Seq transcriptional profiling and gene ontology analysis, Pharmacokinetic studies, and <i>in vivo</i> breast cancer xenograft studies.<br><b>Datasets supporting figures, and supplementary figures and tables: </b>Table <b>Ziegler et. al.xlsx</b> is in .xlsx file format and describes all the datasets (names, dataset format and links to datasets) supporting the figures and supplementary figures and tables in the published article. <br>